中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents

Interventional expert consensus on integrated traditional Chinese and Western medicine for the diagnosis and treatment of hepatocellular carcinoma(trial editionⅠ)

DOI: 10.3969/j.issn.1001-5256.2022.01.010
  • Received Date: 2021-12-08
  • Accepted Date: 2021-12-08
  • Published Date: 2022-01-20
  • This consensus is compiled by the experts of hepatocellular carcinoma(HCC) project team, which is under the "major and difficult diseases-the clinical cooperation project of traditional Chinese medicine and Western medicine" of the State Administration of Traditional Chinese Medicine of China. This HCC project team has established minimally-invasive radical ablation for early stage HCC and transcatheter arterial chemoembolization(TAE/TACE) sequential minimally-invasive interventional ablation for advanced HCC, and on the basis of traditional Chinese Medicine(TCM) theory of "determination of treatment based on differentiation of syndromes" the team has further developed a liver ablation system which is represented by hepatic segment ablation, including interventional embolization of labeled tumors, sequential minimally-invasive local ablation and anatomical mode ablation, and elimination of radiographically visible tumors, etc. Based on the TCM theory of "improving the general condition and eliminating the causative agents", reasonable and suitable therapeutic measures are adopted to improve the body's immune function, to remodel a micro-environment that is unsuitable for tumor growth, and to eliminate radiographically invisible tumors. After long-term efforts, the HCC project team has found out the overall solution of "integrated clinical cooperative treatment of HCC with traditional Chinese and Western medicine". This consensus is characterized by the combination of TCM micro-environment conditioning and micro-invasive ablation, it has fully played the TCM overall therapeutic advantages such as "improving the general condition and eliminating the causative agents", "determination of treatment based on differentiation of syndromes", accurately inactivating tumor with minimally-invasive ablation while effectively preserving the normal anatomical structure, physiological functions and immune functions, etc. The overall therapy combined with local ablation treatment and the TCM conditioning combined with minimally-invasive ablation have initiated a novel mode of minimally-invasive diagnosis and treatment of integrated traditional Chinese and Western medicine in treating HCC. After the implementation of this consensus, the treatment of BCLC stage A HCC can obtain the same radical effect as the open surgery. Moreover, the treatment of BCLC Stage B/C HCC that previously could not be treated with open surgery can also obtain radical effect. The above achievements have made the treatment of HCC entering a novel stage, in which a new mode of human cultural diagnosis and treatment becomes to be employed in clinical practice, and the implementation of this project can maximize the effect of health economics.

     

  • loading
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953. DOI: 10.1002/ijc.31937.
    [3]
    China Association of Chinese Medicine. Guidelines for diagnosis and treatment of cancer in traditional Chinese medicine[M]. Beijing: China Press of Traditional Chinese Medicine, 2008.

    中华中医药学会. 肿瘤中医诊疗指南[M]. 北京: 中国中医药出版社, 2008.
    [4]
    ZHAO WJ, ZHU GQ, WU YM, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: Results of propensity score-weighted analysis[J]. Onco Targets Ther, 2019, 12: 10389-10400. DOI: 10.2147/OTT.S224809.
    [5]
    LIN HS. Traditional Chinese medicine diagnosis and treatment guidelines for malignant tumors[M]. Beijing: People's Medical Publishing House, 2014.

    林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014.
    [6]
    Chinese Societies of Liver Cancer and Clinical Oncology, Chinese Anti-Cancer Association; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Experts consensus on local ablation therapy for liver cancer[J]. Tumor, 2011, 31: 385-388. DOI: 10.3781/j.issn.1000-7431.2011.05.001.

    中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识[J]. 肿瘤, 2011, 31: 385-388. DOI: 10.3781/j.issn.1000-7431.2011.05.001.
    [7]
    Interventional Group, Chinese Society of Radiology, Chinese Medical Association. Expert consensus on standard therapeutic procedures of percutaneous radiofrequency ablation for liver tumor[J]. Chin J Radiol, 2012, 46(7): 581-585. DOI: 10.3760/cma.j.issn.1005-1201.2012.07.001.

    中华医学会放射学分会介入学组. 经皮肝脏肿瘤射频消融治疗操作规范专家共识[J]. 中华放射学杂志, 2012, 46(7): 581-585. DOI: 10.3760/cma.j.issn.1005-1201.2012.07.001.
    [8]
    MERKLE EM, ZECH CJ, BARTOLOZZI C, et al. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging[J]. Eur Radiol, 2016, 26(3): 674-682. DOI: 10.1007/s00330-015-3873-2.
    [9]
    Panel on Technical Management Standards for Tumor Ablation Therapy, National Health and Family Planning Commission of the People's Republic of China. Technical management standards for tumor ablation therapy (2017 edition)[J/CD]. Electronic J Liver Tumor, 2017, 4(4): 6-7. DOI: 10.3969/j.issn.2095-7815.2017.04.004.

    国家卫计委肿瘤消融治疗技术管理规范专家组. 肿瘤消融治疗技术管理规范(2017年版)[J/CD]. 肝癌电子杂志, 2017, 4(4): 6-7. DOI: 10.3969/j.issn.2095-7815.2017.04.004.
    [10]
    BOELLAARD R, DELGADO-BOLTON R, OYEN WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354. DOI: 10.1007/s00259-014-2961-x.
    [11]
    CHALIAN H, TORE HG, HOROWITZ JM, et al. Radiologic assessment of response to therapy: Comparison of RECIST versions 1.1 and 1.0[J]. Radiographics, 2011, 31(7): 2093-2105. DOI: 10.1148/rg.317115050.
    [12]
    Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.

    中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
    [13]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [14]
    ZHENG XY. Guidelines for clinical research of Chinese medicine (new drug) (trial)[M]. Beijing: China Medical Science Press, 2002: 208-213.

    郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 208-213.
    [15]
    SI T, NING XJ, FENG XB, et al. Study on traditional Chinese medicine syndrome of 312 cases of primary liver cancer patients before and after the interventional embolization chemotherapy[J]. J Tradit Chin Med, 2015, 56(19): 1678-1681. DOI: 10.13288/j.11-2166/r.2015.19.016.

    斯韬, 宁雪坚, 冯献斌, 等. 312例原发性肝癌患者血管介入栓塞化疗前后中医证候研究[J]. 中医杂志, 2015, 56(19): 1678-1681. DOI: 10.13288/j.11-2166/r.2015.19.016.
    [16]
    ZHAO HJ, DU J, DONG BW, et al. Primary study on clinical TCM syndrome characteristics after microwave thermal ablation for hepatocellular carcinoma[J]. J Fujian Coll Tradit Chin Med, 2008, 18(3): 1-3. DOI: 10.3969/j.issn.1004-5627.2008.03.001.

    赵红佳, 杜建, 董宝玮, 等. 肝癌患者微波热消融治疗术后中医证候特点[J]. 福建中医学院学报, 2008, 18(3): 1-3. DOI: 10.3969/j.issn.1004-5627.2008.03.001.
    [17]
    AYUSO C, RIMOLA J, VILANA R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines[J]. Eur J Radiol, 2018, 101: 72-81. DOI: 10.1016/j.ejrad.2018.01.025.
    [18]
    ZHENG JS, LI N, YUAN CW. CT-guided ablation therapy of liver tumor[M]. Beijing: People's Medical Publishing House, 2011: 1- 8.

    郑加生, 李宁, 袁春旺. CT引导肝肿瘤消融治疗学[M]. 北京: 人民卫生出版社, 2011: 1- 8.
    [19]
    ZHENG JS, LI N, YUAN CW. Image-guided ablation therapy of tumor[M]. Beijing: People's Medical Publishing House, 2013: 14-16.

    郑加生, 李宁, 袁春旺. 影像引导肿瘤消融治疗学[M]. 北京: 人民卫生出版社, 2013: 14-16.
    [20]
    LONG J, ZHENG JS, SUN B, et al. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: A prospective study[J]. Hepatol Int, 2016, 10(1): 175-184. DOI: 10.1007/s12072-015-9673-6.
    [21]
    YUAN C, YUAN Z, CUI X, et al. Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma[J]. J Cancer Res Ther, 2019, 15(4): 784-792. DOI: 10.4103/jcrt.JCRT_836_18.
    [22]
    ZHENG JS, LONG J, SUN B, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: Extending the indication for ablation?[J]. Clin Radiol, 2014, 69(6): e253-e263. DOI: 10.1016/j.crad.2014.01.015.
    [23]
    LI W, WANG Y, GAO W, et al. HCC with tumor thrombus entering the right atrium and inferior vena cava treated by percutaneous ablation[J]. BMC Surg, 2017, 17(1): 21. DOI: 10.1186/s12893-017-0217-y.
    [24]
    YUAN Z, WANG Y, HU C, et al. Efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and a prognostic nomogram to predict survival[J]. Technol Cancer Res Treat, 2018, 17: 1533033818801362. DOI: 10.1177/1533033818801362.
    [25]
    Society of Interventional Physicians, Chinese Medical Doctor Association. Chinese clinical practice guidelines for transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma[J]. Natl Med J China, 2018, 98: 3811-3819. DOI: 10.3760/cma.j.issn.0376-2491.2018.47.002.

    中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 中华医学杂志, 2018, 98: 3811-3819. DOI: 10.3760/cma.j.issn.0376-2491.2018.47.002.
    [26]
    HAN D, XU YM, YU J, et al. Clinical effect of Dachaihu decoction combined with modified Liujunzi decoction in prevention and treatment of post-embolization syndrome in liver cancer[J]. Beijing J Tradit Chin Med, 2011, 30(11): 842-843. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO201111017.htm

    韩冬, 徐咏梅, 于洁, 等. 大柴胡汤合六君子汤加减防治肝癌栓塞后综合征的临床研究[J]. 北京中医药, 2011, 30(11): 842-843. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO201111017.htm
    [27]
    YANG HN, FAN QS, LIU FQ, et al. Effects of the traditional Chinese medicine Tiaogan Lipi granules on postembolization syndrome induced by transcatheter arterial chemoembolization for hepatocellular carcinoma[J/CD]. Chin J Inter Rad(Electronic Edition), 2021, 9(1): 20-24. DOI: 10.3877/cma.j.issn.2095-5782.2021.01.003.

    杨海宁, 樊庆胜, 刘福全, 等. 中医调肝理脾法防治肝癌栓塞术后综合征的临床观察[J/CD]. 中华介入放射学电子杂志, 2021, 9(1): 20-24. DOI: 10.3877/cma.j.issn.2095-5782.2021.01.003.
    [28]
    HAN Y, HUANG Z, JIANG ZC, et al. Expert consensus on targeted therapy for liver cancer (draft)[J/CD]. Electronic J Liver Tumor, 2020, 7(2): 2-11. DOI: 10.3760/cma.j.cn112137-20210425-00991.

    韩玥, 黄振, 姜志超, 等. 肝癌靶向治疗专家共识(草案)[J/CD]. 肝癌电子杂志, 2020, 7(2): 2-11. DOI: 10.3760/cma.j.cn112137-20210425-00991.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Article Metrics

    Article views (1395) PDF downloads(423) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return